Clinical Trials

Urinary Bladder Neoplasms

NCT04689828 2026-03-23

PSMAfore

469 enrolled 11 charts 3 FDA

Prostatic Neoplasms

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT03945773 2026-03-13

CaboPoint

127 enrolled 17 charts

Carcinoma, Renal Cell

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT05526248 2026-03-11

ARAMON

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT03142334 2026-03-10

KEYNOTE-564

994 enrolled 10 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT04736199 2026-02-27

ARANOTE

669 enrolled 16 charts

Prostatic Neoplasms

NCT05968599 2026-02-25

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Completed

2,731 enrolled 14 charts

Prostatic Neoplasms, Castration-Resistant

NCT01171898 2026-02-24

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Phase 1/2 Completed

127 enrolled 16 charts

Prostatic Neoplasms

NCT01314118 2026-02-24

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

131 enrolled 12 charts

Prostatic Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT03995888 2026-02-12

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Phase 1 Completed

24 enrolled 10 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Prostatic Neoplasms

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT03898180 2026-02-05

LEAP-011

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 2 FDA

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT03459846 2026-01-30

BAYOU

154 enrolled 13 charts

Urinary Bladder Neoplasms

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

895 enrolled 19 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT05701007 2026-01-29

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

292 enrolled 21 charts

Prostatic Neoplasms

NCT04165317 2026-01-22

CREST

1,068 enrolled 20 charts

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

43 enrolled 15 charts

Advanced and Metastatic Urothelial Cancer

NCT06072196 2025-12-31

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Completed

3,017 enrolled 5 charts

Prostatic Neoplasms

NCT02854436 2025-12-22

Galahad

289 enrolled 18 charts